Cargando…

Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas

PURPOSE: OncoHepa test is a multigene expression profile test developed for assessment of hepatocellular carcinoma (HCC) prognosis. Multiplication of α-FP, des-γ-carboxy prothrombin (DCP) and tumor volume (TV) gives the α-FP-DCP-volume (ADV) score, which is also developed for assessment of HCC progn...

Descripción completa

Detalles Bibliográficos
Autores principales: Ha, Su-Min, Hwang, Shin, Park, Jin Young, Lee, Young-Joo, Kim, Ki-Hun, Song, Gi-Won, Jung, Dong-Hwan, Yu, Yun-Suk, Kim, Jinpyo, Lee, Kyoung-Jin, Tak, Eunyoung, Park, Yo-Han, Lee, Sung-Gyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Surgical Society 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255750/
https://www.ncbi.nlm.nih.gov/pubmed/30505821
http://dx.doi.org/10.4174/astr.2018.95.6.303
_version_ 1783374008248434688
author Ha, Su-Min
Hwang, Shin
Park, Jin Young
Lee, Young-Joo
Kim, Ki-Hun
Song, Gi-Won
Jung, Dong-Hwan
Yu, Yun-Suk
Kim, Jinpyo
Lee, Kyoung-Jin
Tak, Eunyoung
Park, Yo-Han
Lee, Sung-Gyu
author_facet Ha, Su-Min
Hwang, Shin
Park, Jin Young
Lee, Young-Joo
Kim, Ki-Hun
Song, Gi-Won
Jung, Dong-Hwan
Yu, Yun-Suk
Kim, Jinpyo
Lee, Kyoung-Jin
Tak, Eunyoung
Park, Yo-Han
Lee, Sung-Gyu
author_sort Ha, Su-Min
collection PubMed
description PURPOSE: OncoHepa test is a multigene expression profile test developed for assessment of hepatocellular carcinoma (HCC) prognosis. Multiplication of α-FP, des-γ-carboxy prothrombin (DCP) and tumor volume (TV) gives the α-FP-DCP-volume (ADV) score, which is also developed for assessment of HCC prognosis. METHODS: The predictive powers of OncoHepa test and ADV score were validated in 35 patients who underwent curative hepatic resection for naïve solitary HCCs ≤5 cm. RESULTS: Median tumor diameter was 3.0 cm. Tumor recurrence and patient survival rates were 28.6% and 100% at 1 year, 48.6% and 82.9% at 3 years, and 54.3% and 71.4% at 5 years, respectively. The site of first tumor recurrence was the remnant liver in 18, lung in 1, and the peritoneum in 1. All patients with HCC recurrence received locoregional treatment. OncoHepa test showed marginal prognostic significance for tumor recurrence and patient survival. ADV score at 4log also showed marginal prognostic difference with respect to tumor recurrence and patient survival. Combination of these 2 tests resulted in greater prognostic significance for both tumor recurrence (P = 0.046) and patient survival (P = 0.048). CONCLUSION: Both OncoHepa test and ADV score have considerably strong prognostic power, thus individual and combined findings of OncoHepa test and ADV score will be helpful to guide postresection surveillance in patients with solitary HCCs ≤5 cm.
format Online
Article
Text
id pubmed-6255750
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Korean Surgical Society
record_format MEDLINE/PubMed
spelling pubmed-62557502018-12-01 Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas Ha, Su-Min Hwang, Shin Park, Jin Young Lee, Young-Joo Kim, Ki-Hun Song, Gi-Won Jung, Dong-Hwan Yu, Yun-Suk Kim, Jinpyo Lee, Kyoung-Jin Tak, Eunyoung Park, Yo-Han Lee, Sung-Gyu Ann Surg Treat Res Original Article PURPOSE: OncoHepa test is a multigene expression profile test developed for assessment of hepatocellular carcinoma (HCC) prognosis. Multiplication of α-FP, des-γ-carboxy prothrombin (DCP) and tumor volume (TV) gives the α-FP-DCP-volume (ADV) score, which is also developed for assessment of HCC prognosis. METHODS: The predictive powers of OncoHepa test and ADV score were validated in 35 patients who underwent curative hepatic resection for naïve solitary HCCs ≤5 cm. RESULTS: Median tumor diameter was 3.0 cm. Tumor recurrence and patient survival rates were 28.6% and 100% at 1 year, 48.6% and 82.9% at 3 years, and 54.3% and 71.4% at 5 years, respectively. The site of first tumor recurrence was the remnant liver in 18, lung in 1, and the peritoneum in 1. All patients with HCC recurrence received locoregional treatment. OncoHepa test showed marginal prognostic significance for tumor recurrence and patient survival. ADV score at 4log also showed marginal prognostic difference with respect to tumor recurrence and patient survival. Combination of these 2 tests resulted in greater prognostic significance for both tumor recurrence (P = 0.046) and patient survival (P = 0.048). CONCLUSION: Both OncoHepa test and ADV score have considerably strong prognostic power, thus individual and combined findings of OncoHepa test and ADV score will be helpful to guide postresection surveillance in patients with solitary HCCs ≤5 cm. The Korean Surgical Society 2018-12 2018-11-26 /pmc/articles/PMC6255750/ /pubmed/30505821 http://dx.doi.org/10.4174/astr.2018.95.6.303 Text en Copyright © 2018, the Korean Surgical Society http://creativecommons.org/licenses/by-nc/4.0/ Annals of Surgical Treatment and Research is an Open Access Journal. All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Ha, Su-Min
Hwang, Shin
Park, Jin Young
Lee, Young-Joo
Kim, Ki-Hun
Song, Gi-Won
Jung, Dong-Hwan
Yu, Yun-Suk
Kim, Jinpyo
Lee, Kyoung-Jin
Tak, Eunyoung
Park, Yo-Han
Lee, Sung-Gyu
Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas
title Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas
title_full Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas
title_fullStr Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas
title_full_unstemmed Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas
title_short Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas
title_sort validation of the oncohepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255750/
https://www.ncbi.nlm.nih.gov/pubmed/30505821
http://dx.doi.org/10.4174/astr.2018.95.6.303
work_keys_str_mv AT hasumin validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas
AT hwangshin validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas
AT parkjinyoung validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas
AT leeyoungjoo validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas
AT kimkihun validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas
AT songgiwon validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas
AT jungdonghwan validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas
AT yuyunsuk validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas
AT kimjinpyo validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas
AT leekyoungjin validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas
AT takeunyoung validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas
AT parkyohan validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas
AT leesunggyu validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas